Search Results

FundaMental Pharma GmbH (‘FundaMental’ or ’the Company’), a neuroscience company developing first-in-class small molecule inhibitors for treatment of a range of neurodegenerative diseases, today announces the publication of a groundbreaking study by Neurobiologists in Heidelberg using FundaMental Pharma’s small molecule TwinF interface inhibitor, FP802.

Pharma’s reprieve from Donald Trump’s tariffs is expected to be temporary, with Leerink analysts anticipating possible sector-specific duties “in the next month or so.”

Johnson & Johnson’s Joaquin Duato is no longer the highest paid CEO in pharma. Meanwhile, just two women make the top 10.

Playing both sides of trade war, pharma companies are asking for certain compensations for scientific innovation and a smoother regulatory framework.

M&A and IPOs got off to a quick start in 2025 only to crash into a wall of policy challenges. Upfront payment for licensing transactions, however, grew as pharmas looked for less-risky deals.

Trump could use the findings of the probe to impose certain trade restrictions on pharma products, including tariffs.

Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of rivalry that includes blockbuster drugs Keytruda, Humira and Eliquis.

Accuray Incorporated announced that long-term customer Heidelberg University Hospital in Heidelberg, Germany, has selected the company’s Radixact® System, equipped with its proprietary ClearRT®, Synchrony® and VOLO™ Ultra Optimizer solutions, to help transform their approach to cancer care.

Pharma stocks went on a wild ride Wednesday amid whiplashing tariff threats from the U.S. president.